{"analyses":[{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","groupDescription":"Hazard ratios (HR) were estimated by a Cox regression model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"= 0.0106","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Log rank (Stratified)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.6","upperLimit":"12.0","value":"9.7"},{"groupId":"OG001","lowerLimit":"9.7","upperLimit":"16.0","value":"12.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as dead at the time of analysis was censored at the date when they were last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received docetaxel 75 milligram per squared meters (mg/m\\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.","id":"OG000","title":"Docetaxel"},{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"ITT population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned.","reportingStatus":"POSTED","timeFrame":"From the time of randomization to the date of death due to any cause or up to data cut off date: 01 Dec 2015 (up to 28 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}